Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Prediction of Cognitive Heterogeneity in Parkinson's Disease: A 4-Year Longitudinal Study Using Clinical, Neuroimaging, Biological and Electrophysiological Biomarkers

  • Puig-Davi, Arnau
  • Martinez-Horta, Saul
  • Pérez-Carasol, Laura
  • Horta-Barba, Andrea
  • Ruiz-Barrio, Iñigo
  • Aracil-Bolaños, Ignacio
  • Pérez-González, Rocío
  • Rivas-Asensio, Elisa
  • Sampedro, Frederic
  • Campolongo, Antonia
  • Pagonabarraga, Javier
  • Kulisevsky, Jaime
[Objective] Cognitive impairment in Parkinson's disease (PD) can show a very heterogeneous trajectory among patients. Here, we explored the mechanisms involved in the expression and prediction of different cognitive phenotypes over 4 years., [Methods] In 2 independent cohorts (total n = 475), we performed a cluster analysis to identify trajectories of cognitive progression. Baseline and longitudinal level II neuropsychological assessments were conducted, and baseline structural magnetic resonance imaging, resting electroencephalogram and neurofilament light chain plasma quantification were carried out. Linear mixed-effects models were used to study longitudinal changes. Risk of mild cognitive impairment and dementia were estimated using multivariable hazard regression. Spectral power density from the electroencephalogram at baseline and source localization were computed., [Results] Two cognitive trajectories were identified. Cluster 1 presented stability (PD-Stable) over time, whereas cluster 2 showed progressive cognitive decline (PD-Progressors). The PD-Progressors group showed an increased risk for evolving to PD mild cognitive impairment (HR 2.09; 95% CI 1.11–3.95) and a marked risk for dementia (HR 4.87; 95% CI 1.34–17.76), associated with progressive worsening in posterior-cortical-dependent cognitive processes. Both clusters showed equivalent clinical and sociodemographic characteristics, structural magnetic resonance imaging, and neurofilament light chain levels at baseline. Conversely, the PD-Progressors group showed a fronto-temporo-occipital and parietal slow-wave power density increase, that was in turn related to worsening at 2 and 4 years of follow-up in different cognitive measures., [Interpretation] In the absence of differences in baseline cognitive function and typical markers of neurodegeneration, the further development of an aggressive cognitive decline in PD is associated with increased slow-wave power density and with a different profile of worsening in several posterior-cortical-dependent tasks., This study was funded by competitive grants awarded by Fundació la Marató de TV3 (grants #2014/U/477 and #20142910), and by Fondo de Investigaciones Sanitarias from the Instituto de Salud Carlos III (ISCIII) and Fondo Europeo de Desarrollo Regional grants #PI15/00962 and #PI18/01717. A.P.-D. is the recipient of a predoctoral grant from the Government of Andorra (ATC027-AND/2021), I.R.-B is the recipient of a Rio Hortega contract from ISCIII (CM22/00072). and I.A.-B. is the recipient of a Juan Rodés contract from ISCIII (JR22/00059). The research group also receives funds from CERCA (CEntres de Recerca de CAtalunya) and CIBERNED (Centro de Investigación Biomédica en Red de enfermedades NEuroDegenerativas)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Parkinson's Disease, Impulsivity Does Not Cause Impulse Control Disorders but Boosts Their Severity

  • Marín Lahoz, Juan|||0000-0003-0008-2360
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Martínez-Horta, Saul|||0000-0003-0125-7249
  • Fernandez de Bobadilla, Ramón
  • Pascual Sedano, Berta María|||0000-0002-9298-8241
  • Pérez Pérez, Jesús|||0000-0002-9835-0484
  • Gironell, Alexandre|||0000-0003-2109-9030
  • Kulisevsky, Jaime|||0000-0003-4870-1431
Introduction: Impulse control disorders (ICDs) are a common complication of Parkinson's disease (PD) receiving dopamine agonist (DAA) Impulsivity is considered an underlying mechanism but evidence of this relationship is scarce. To explore the relationship between impulsivity and the presence and severity of ICD in PD. Methods: Prospective cross-sectional study of consecutive PD outpatients. Patients with dementia or previously known ICDs were excluded. Two measures of impulsivity were assessed: Barratt Impulsiveness Scale (BIS-11) for impulsiveness trait (main exposure) and commission errors in the Continuous Performance Test (CE) for motor inhibition. Main outcomes were diagnosis of ICD based on a comprehensive clinical interview and severity of ICD based on the Questionnaire for Impulsive-Compulsive Disorders. Results: Of 100 patients (mean [SD] age, 67.2 [8.8], 54 male), 31 had ICD. Patients with ICDs were 5.3 years younger (p = 0.01), used more frequently dopamine agonist (p = 0.02), alcohol (p = 0.009) and tobacco (p = 0.02). They were not more impulsive on BIS-11 (56 vs. 58, p = 0.23, adjusted p = 0.46) and CE (p = 0.96). No relationship was found between dopaminergic medications and impulsivity or ICD severity. Among patients with ICD, impulsivity was correlated with ICD severity (BIS-11 r = 0.33, p = 0.001, adjusted p = 0.002, CE r = 0.53, p = 0.006). Multivariate regression analysis confirmed the independent predictive role of both measures. Conclusions: Impulsivity is not associated with increased prevalence of ICD in PD but it is strongly linked to ICD severity. When considering dopamine replacement therapy, assessment of impulsivity may be a useful approach to detect those patients at risk of severe forms of ICD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Randomized Clinical Trial to Evaluate the Effects of Safinamide on Apathetic Non-demented Patients With Parkinson's Disease

  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Martínez-Horta, Saul|||0000-0003-0125-7249
  • Campolongo, Antonia|||0000-0002-7962-3264
  • Pascual Sedano, Berta María|||0000-0002-9298-8241
  • Marín Lahoz, Juan|||0000-0003-0008-2360
  • Bejr-kasem, Helena|||0000-0001-8828-5976
  • Aracil-Bolaños, Ignacio|||0000-0002-8246-5025
  • Horta-Barba, Andrea|||0000-0003-0050-5466
  • Puig-Davi, Arnau|||0000-0001-8883-4947
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
Background: Apathy is highly prevalent and disabling in Parkinson's disease (PD). Pharmacological options for its management lack sufficient evidence. Objective: We studied the effects of safinamide on apathy in PD. Methods: Prospective, 24-week, two-site, randomized, double-blind, placebo-controlled, parallel-group exploratory study in non-demented PD on stable dopaminergic therapy randomized 1:1 to adjunct safinamide (50 mg/day for 2 weeks and 100 mg/day for 22 weeks) or placebo. The primary endpoint was the mean change from baseline to week 24 on the Apathy Scale (AS) total score. Secondary endpoints included changes in cognition, activities of daily living, motor scores, the impression of change, and safety and tolerability measures. Results: In total, 30 participants (active treatment = 15; placebo = 15; 80% showing clinically significant apathetic symptoms according to the AS) were enrolled, and included in the intention-to-treat analysis. Change in AS (ANOVA) showed a trend to significance [p = 0.059] mediated by a more marked decrease in AS score with safinamide (-7.5 ± 6.9) than with placebo (-2.8 ± 5.7). Post-hoc analysis (paired t-test) showed a significant positive change in the AS score between 12-week and 24-week [p = 0.001] only in the active group. No significant or trend changes were found for any of the secondary outcome variables. Adverse events were few and only mild in both treatment groups. Conclusions: Safinamide was safe and well-tolerated, but failed to provide evidence of improved apathy. The positive trend observed in the post-hoc analyses deserves to be studied in depth in larger studies. Trial Registration: EudraCT 2017-003254-17.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Predicting Impulse Control Disorders in Parkinson Disease through Incentive Biomarkers

  • Marín Lahoz, Juan|||0000-0003-0008-2360
  • Martínez-Horta, Saul|||0000-0003-0125-7249
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Horta-Barba, Andrea|||0000-0003-0050-5466
  • Aracil-Bolaños, Ignacio|||0000-0002-8246-5025
  • Bejr-kasem, Helena|||0000-0001-8828-5976
  • Sampedro, Frederic|||0000-0002-3933-1355
  • Campolongo, Antonia|||0000-0002-7962-3264
  • Kulisevsky, Jaime|||0000-0003-4870-1431
Objective: This study was undertaken to evaluate whether the feedback-related negativity (FRN)-a neurophysiological marker of incentive processing-can be used to predict the development of impulse control disorders (ICDs) in Parkinson disease (PD). Methods: The longitudinal cohort consisted of consecutive nondemented PD patients with no ICD history. We recorded FRN signals while they performed a gambling task. We calculated the mean amplitude difference between losses and gains (FRNdiff) to be used as a predictor of future ICD development. We performed prospective biannual follow-up assessments for 30 months to detect incident ICDs. Finally, we evaluated how basal FRNdiff was associated with posterior development of ICDs using survival models. Results: Between October 7, 2015 and December 16, 2016, we screened 120 patients. Among them, 94 patients performed the gambling and 92 completed the follow-up. Eighteen patients developed ICDs during follow-up, whereas 74 remained free of ICDs. Baseline FRNdiff was greater in patients who developed ICDs than in those who did not (-2.33μV vs -0.84μV, p = 0.001). No other significant baseline differences were found. The FRNdiff was significantly associated with ICD development in the survival models both when not adjusted (hazard ratio [HR] = 0.73, 95% confidence interval [CI] = 0.58-0.91, p = 0.006) and when controlling for dopamine replacement therapy, sex, and age (HR = 0.74, 95% CI = 0.55-0.97, p = 0.035). None of the impulsivity measures evaluated was related to ICD development. Interpretation: Reward-processing differences measured by FRN signals precede ICD development in PD. This neurophysiological marker permits identification of patients with high risk of ICD development. ANN NEUROL 2022;92:974-984.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Early gray matter volume loss in MAPT H1H1 de Novo PD patients, A possible association with cognitive decline

  • Sampedro, Frederic|||0000-0002-3933-1355
  • Marín Lahoz, Juan|||0000-0003-0008-2360
  • Martínez-Horta, Saul|||0000-0003-0125-7249
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Kulisevsky, Jaime|||0000-0003-4870-1431
The MAPT H1 haplotype has been identified as a predictor of cognitive decline in Parkinson's disease (PD). However, its underlying pathological mechanisms have not been fully established. In this work, using a cohort of 120 de novo PD patients with preserved cognition from the Parkinson's Progression Markers Initiative (PPMI) database, we found that patients who were homozygous for MAPT H1 had less gray matter volume (GMV) and greater 1-year GMV loss than patients without this genetic profile. Importantly, these changes were associated with a longitudinal worsening of cognitive indicators. Our findings suggest that early GMV loss in MAPT H1H1 PD patients increases their risk to develop cognitive decline.